A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
Indications Smoldering multiple myeloma
Focus Therapeutic Use

11 Jun 2024 Planned primary completion date changed from 31 Oct 2026 to 1 Apr 2025.
11 Jun 2024 Status changed from recruiting to active, no longer recruiting.
31 Oct 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 2 Nov 2022 to 6 Nov 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com